[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624480":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":33,"locations":25,"responsibleParty":39,"collaborators":25,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":25,"eligibilityCriteria":46,"healthyVolunteers":43,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":25,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":66,"whyStopped":25,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":25},{"fullName":5,"class":6},"Huazhong University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A (liposomal bupivacene）","EXPERIMENTAL","In the experimental group, 15 mL of a mixture containing liposomal bupivacaine plus plain bupivacaine is deposited around each target nerve (20 mL liposomal bupivacene, 266 mg, combined with 10 mL 0.75 % plain bupivacaine, total 30 mL).",[13],"Drug: Group A（ liposomal bupivacene）",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B（bupivacene）","ACTIVE_COMPARATOR","The control group receives 15 mL of 0.25 % plain bupivacaine around each nerve. Unlike the clear solution of plain bupivacaine, liposomal bupivacaine has a distinctive milky-white appearance.",[19],"Drug: Group B（bupivacene）",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Group A（ liposomal bupivacene）",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"affiliation":31,"role":32},"Wei Mei","Tongji Medical College, Huazhong University of Science and Technology","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Wei Xia","CONTACT","+8615623068980","jamesxia@163.com",{"type":32,"investigatorFullName":30,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"clinical professor","100624480","phase-4-bupivacaine-liposome-versus-bupivacaine-for-ultrasound-guided-suprascapular-nerve-combined-with-axillary-nerve-block-in-analgesia-after-arthroscopic-shoulder-surgery-100624480",false,"NCT07410182","Bupivacaine Liposome Versus Bupivacaine for Ultrasound-Guided Suprascapular Nerve Combined With Axillary Nerve Block in Analgesia After Arthroscopic Shoulder Surgery","Inclusion Criteria:\n\n1. Aged 18-60 years\n2. ASA physical status I-II\n3. Undergoing unilateral arthroscopic shoulder surgery\n4. The Operative time between 1and 4 hours\n\nExclusion Criteria:\n\n1. Anticipated operative time \\\u003C 1 h or \\> 4 h\n2. Severe cardiopulmonary insufficiency\n3. Hepatic or renal dysfunction\n4. Coagulopathy\n5. Diabetic peripheral neuropathy\n6. History of nerve injury on the operative side\n7. Skin infection at the block site\n8. Allergy to amide local anesthetics\n9. Refusal to participate or any other condition deemed unsuitable.","ALL","18 Years","60 Years",{"count":51,"type":52},60,"ESTIMATED","INTERVENTIONAL",[55],"PHASE4","This trial is designed to compare the post-operative analgesic efficacy and safety of liposomal bupivacaine versus plain bupivacaine when both are used for ultrasound-guided combined suprascapular and axillary nerve block in patients undergoing elective arthroscopic shoulder surgery.",[58,59,60,61,62],"Arthroscopic Shoulder Surgery","Ultrasound Guided Nerve Block","Bupivacaine","Suprascapular Nerve Block","Axillary Nerve Block",[58,64,65,62],"ultrasound guided nerve block","suprascapular nerve block","NOT_YET_RECRUITING","2026-02-07",{"date":69,"type":70},"2026-02-13","ACTUAL",{"date":72,"type":52},"2026-03-01",{"date":74,"type":52},"2026-12-30",{"name":5,"class":6}]